Estrogen/Progesterone receptor (ER/PR)-positive tumor was lower in the LRT group (84% vs. 89%, p = 0.04), although hormonal therapy was administered equally (85% in both groups, p = 0.99). The gene discussed is ESR1; the disease is neoplasm.